Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'METASTATIC BREAST CANCER' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 722 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kruger, W; Kroger, N; Togel, F; Badbaran, A; Renges, H; Gieseking, F; Gutensohn, K; Janicke, F; Zander, AR
      Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells

      JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH
    2. Zogakis, TG; Libutti, SK
      General aspects of anti-angiogenesis and cancer therapy

      EXPERT OPINION ON BIOLOGICAL THERAPY
    3. Preti, RA; Lazarus, HM; Winter, J; Stadtmauer, EA; Nadasi, S; McMannis, J; Karandish, S; Jennis, A; Goldberg, SL; Pecora, AL
      Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer

      CYTOTHERAPY
    4. Bockmann, B; Grill, HJ; Giesing, M
      Molecular characterization of minimal residual cancer cells in patients with solid tumors

      BIOMOLECULAR ENGINEERING
    5. Frenkel, GD; Caffrey, PB
      A prevention strategy for circumventing drug resistance in cancer chemotherapy

      CURRENT PHARMACEUTICAL DESIGN
    6. Gray, RE; Sinding, C; Fitch, MI
      Navigating the social context of metastatic breast cancer: reflections on a project linking research to drama

      HEALTH
    7. Domen, J
      The role of apoptosis in regulating hematopoietic stem cell numbers

      APOPTOSIS
    8. Aboagye, EO; Price, PM; Jones, T
      In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography

      DRUG DISCOVERY TODAY
    9. Harrington, KJ
      Liposomal cancer chemotherapy: current clinical applications and future prospects

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    10. Zwick, E; Bange, J; Ullrich, A
      Receptor tyrosine kinase signalling as a target for cancer intervention strategies

      ENDOCRINE-RELATED CANCER
    11. Johnson, PWM
      The therapeutic use of antibodies for malignancy

      TRANSFUSION CLINIQUE ET BIOLOGIQUE
    12. Buchler, P; Reber, HA; Buchler, MC; Roth, MA; Buchler, MW; Friess, H; Isacoff, WH; Hines, OJ
      Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)

      JOURNAL OF GASTROINTESTINAL SURGERY
    13. Margolin, K; Synold, T; Longmate, J; Doroshow, JH
      Methodologic guidelines for the design of high-dose chemotherapy regimens

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    14. Kummar, S; Ishii, A; Yang, HK; Venzon, DJ; Kim, SJ; Gress, RE
      Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-beta 1

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    15. Peng, LS; Penichet, ML; Dela Cruz, JS; Sampogna, SL; Morrison, SL
      Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3)

      JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    16. Nicoletti, MI; Valoti, G; Giannakakou, P; Zhan, ZR; Kim, JH; Lucchini, V; Landoni, F; Mayo, JG; Giavazzi, R; Fojo, T
      Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-anticancer drug screen: Correlation with sensitivity to microtubule active agents

      CLINICAL CANCER RESEARCH
    17. Minotti, G; Saponiero, A; Licata, S; Menna, P; Calafiore, AM; Teodori, G; Gianni, L
      Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium

      CLINICAL CANCER RESEARCH
    18. Vahdat, L; Papadopoulos, K; Lange, D; Leuin, S; Kaufman, E; Donovan, D; Frederick, D; Bagiella, E; Tiersten, A; Nichols, G; Garrett, T; Savage, D; Antman, K; Hesdorffer, CS; Balmaceda, C
      Reduction of paclitaxel-induced peripheral neuropathy with glutamine

      CLINICAL CANCER RESEARCH
    19. Laurie, SA; Pfister, DG; Kris, MG; Tong, WP; Chronowski, G; Pisters, KWM; Heelan, RT; Sirotnak, FM
      Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin

      CLINICAL CANCER RESEARCH
    20. Lyass, O; Hubert, A; Gabizon, AA
      Phase I study of doxil-cisplatin combination chemotherapy in patients withadvanced malignancies

      CLINICAL CANCER RESEARCH
    21. Smith, MA; Anderson, B
      Phase II window studies: 10 years of experience and counting

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    22. Lagasse, E; Shizuru, JA; Uchida, N; Tsukamoto, A; Weissman, IL
      Toward regenerative medicine

      IMMUNITY
    23. Heldin, CH
      Signal transduction: Multiple pathways, multiple options for therapy

      STEM CELLS
    24. Schneeweiss, A; Hensel, M; Goerner, R; Khbeis, T; Hohaus, S; Egerer, G; Solomayer, E; Haas, R; Grischke, EM; Bastert, G; Ho, AD
      Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer

      STEM CELLS
    25. Balducci, L; Hardy, CL; Lyman, GH
      Hematopoietic growth factors in the older cancer patient

      CURRENT OPINION IN HEMATOLOGY
    26. Mankoff, DA; Bellon, JR
      Positron-emission tomographic imaging of cancer: Glucose metabolism and beyond

      SEMINARS IN RADIATION ONCOLOGY
    27. Wolff, AC
      Systemic therapy

      CURRENT OPINION IN ONCOLOGY
    28. van Ojik, HH; Valerius, T
      Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    29. Hori, T; Kodama, H; Nishimura, S; Hatano, T; Okamura, R; Fujii, K; Kudo, T; Inamoto, T; Sawai, K; Kobayashi, M; Ogawa, H; Yoshimura, N; Hiraoka, M
      A randomized study comparing oral and standard regimens for metastatic breast cancer

      ONCOLOGY REPORTS
    30. Brugnatelli, S; Riccardi, A; Danova, M; Pugliese, P; Tinelli, C; Luchena, G; Bernardo, A; Giardina, G; Fava, S; Montanari, G; Pedrotti, C; Poli, AM
      Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study

      ONCOLOGY REPORTS
    31. Bacci, G; Ferrari, S; Longhi, A; Forni, C; Giacomini, S; Lari, S; Versari, M
      Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy

      ONCOLOGY REPORTS
    32. Danova, M; Porta, C; Ferrari, S; Riccardi, A
      Strategies of medical treatment for metastatic breast cancer

      INTERNATIONAL JOURNAL OF ONCOLOGY
    33. Mantovani, G; Maccio, A; Madeddu, C; Massa, E; Mudu, MC; Mulas, C; Gramignano, G; Massidda, S; Murgia, V; Lusso, MR; Mura, L
      Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy

      INTERNATIONAL JOURNAL OF ONCOLOGY
    34. Kaufmann, M; von Minckwitz, G
      The emerging role of hormonal ablation as adjuvant therapy in node+ and node- pre-/perimenopausal patients

      BREAST
    35. Marty, M
      Liposomal doxorubicin (Myocet (TM)) and conventional anthracyclines: a comparison

      BREAST
    36. Namer, M; Soler-Michel, P; Turpin, F; Chinet-Charrot, P; de Gislain, C; Pouillart, P; Delozier, T; Luporsi, E; Etienne, PL; Schraub, S; Eymard, JC; Serin, D; Ganem, G; Calais, G; Maillart, P; Colin, P; Trillet-Lenoir, V; Prevost, G; Tigaud, D; Clavere, P; Marti, P; Romieu, C; Wendling, JL
      Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer

      EUROPEAN JOURNAL OF CANCER
    37. Smorenburg, CH; Sparreboom, A; Bontenbal, M; Verweij, J
      Combination chemotherapy of the taxanes and antimetabolites: its use and limitations

      EUROPEAN JOURNAL OF CANCER
    38. Miles, DW; Smith, IE; Coleman, RE; Calvert, AH; Lind, MJ
      A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer

      EUROPEAN JOURNAL OF CANCER
    39. Baselga, J
      Clinical trials of Herceptin (R) (trastuzumab)

      EUROPEAN JOURNAL OF CANCER
    40. Vogel, C; Cobleigh, MA; Tripathy, D; Gutheil, JC; Harris, LN; Fehrenbacher, L; Slamon, DJ; Murphy, M; Novotny, WF; Burchmore, M; Shak, S; Stewart, SJ
      First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report

      EUROPEAN JOURNAL OF CANCER
    41. Gieseg, MA; de Bock, C; Ferguson, LR; Denny, WA
      Evidence for epidermal growth factor receptor-enhanced chemosensitivity incombinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033

      ANTI-CANCER DRUGS
    42. Takeda, Y; Yoshizaki, I; Nonaka, Y; Yanagie, H; Matsuzawa, A; Eriguchi, M
      Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo

      ANTI-CANCER DRUGS
    43. Waltmire, CN; Alberts, DS; Dorr, RT
      Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer

      ANTI-CANCER DRUGS
    44. Li, N; van Agthoven, M; Willemse, PHB; Uyl-de Groot, CA
      A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer

      ANTI-CANCER DRUGS
    45. Jagodic, M; Cufer, T; Zakotnik, B; Cervek, J
      Selection of candidates for oral etoposide salvage chemotherapy in heavilypretreated breast cancer patients

      ANTI-CANCER DRUGS
    46. Aapro, M; Rowinsky, E
      Docetaxel: assessing a range of activity

      ANTI-CANCER DRUGS
    47. Brandt, R; Wong, AML; Hynes, NE
      Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells providea novel orthotopic tumor model for testing anti-cancer agents

      ONCOGENE
    48. Bayne, MC; Illidge, TM
      Hypercalcaemia, parathyroid hormone-related protein and malignancy

      CLINICAL ONCOLOGY
    49. Faller, H
      Coping and survival among cancer patients. Review of the literature and results of a study with lung cancer patients

      PSYCHOTHERAPEUT
    50. Yamada, Y; Shirao, K; Ohtsu, A; Boku, N; Hyodo, I; Saitoh, H; Miyata, Y; Taguchi, T
      Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions

      ANNALS OF ONCOLOGY
    51. van Putten, JWG; Kerbush, T; Smit, EF; van Rijswijk, R; Beijnen, JH; Sleijfer, DT; Groen, HJM
      Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer

      ANNALS OF ONCOLOGY
    52. Alexopoulos, A; Kouroussis, C; Malamos, N; Kakolyris, S; Kalbakis, K; Kosmas, C; Mavroudis, D; Agelaki, S; Vlachonicolis, J; Sarra, E; Rigatos, G; Georgoulias, V
      Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study

      ANNALS OF ONCOLOGY
    53. Pierga, JY; Robain, M; Jouve, M; Asselain, B; Dieras, V; Beuzeboc, P; Palangie, T; Dorval, T; Extra, JM; Scholl, S; Pouillart, P
      Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients

      ANNALS OF ONCOLOGY
    54. Fountzilas, G; Tsavdaridis, D; Kalogera-Fountzila, A; Christodoulou, C; Timotheadou, E; Kalofonos, C; Kosmidis, P; Adamou, A; Papakostas, P; Gogas, H; Stathopoulos, G; Razis, E; Bafaloukos, D; Skarlos, D
      Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer - A Hellenic Cooperative Oncology Group phase IIstudy

      ANNALS OF ONCOLOGY
    55. Fogli, S; Danesi, R; Braud, FD; Pas, TD; Curigliano, G; Giovannetti, E; Del Tacca, M
      Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer

      ANNALS OF ONCOLOGY
    56. Stemmler, HJ; Gutschow, K; Sommer, H; Malekmohammadi, M; Kentenich, C; Forstpointner, R; Geuenich, S; Bischoff, J; Hiddemann, W; Heinemann, V
      Weekly docetaxel (Taxotere (R)) in patients with metastatic breast cancer

      ANNALS OF ONCOLOGY
    57. Cara, S; Tannock, IF
      Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance

      ANNALS OF ONCOLOGY
    58. Bengala, C; Pazzagli, I; Innocenti, F; Donati, S; Favre, C; Menconi, MC; Greco, F; Danesi, R; Orlandini, C; Guarneri, V; Del Tacca, M; Conte, PF
      High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)

      ANNALS OF ONCOLOGY
    59. Ryberg, M; Nielsen, D; Osterlind, K; Skovsgaard, T; Dombernowsky, P
      Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy

      ANNALS OF ONCOLOGY
    60. Baselga, J; Albanell, J
      Mechanism of action of anti-HER2 monoclonal antibodies

      ANNALS OF ONCOLOGY
    61. Leyland-Jones, B; Arnold, A; Gelmon, K; Verma, S; Ayoub, JP; Seidman, A; Dias, R; Howell, J; Rakhit, A
      Pharmacologic insights into the future of trastuzumab

      ANNALS OF ONCOLOGY
    62. Baselga, J
      Phase I and II clinical trials of trastuzumab

      ANNALS OF ONCOLOGY
    63. Eiermann, W
      Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

      ANNALS OF ONCOLOGY
    64. Gianni, L
      Tolerability in patients receiving trastuzumab with or without chemotherapy

      ANNALS OF ONCOLOGY
    65. Bell, R
      Ongoing trials with trastuzumab in metastatic breast cancer

      ANNALS OF ONCOLOGY
    66. Kano, Y; Akutsu, M; Tsunoda, S; Suzuki, K; Yazawa, Y; Furukawa, Y
      Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro

      JAPANESE JOURNAL OF CANCER RESEARCH
    67. Horowitz, MM; Loberiza, FR; Bredeson, CN; Rizzo, JD; Nugent, ML
      Transplant registries: Guiding clinical decisions and improving outcomes

      ONCOLOGY-NEW YORK
    68. Ibrahim, NK; Valero, V; Rahman, Z; Theriault, RL; Walters, RS; Buzdar, AU; Booser, DJ; Holmes, FA; Murray, DJ; Willey, J; Bast, R; Hortobagyi, GN
      Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation

      CANCER INVESTIGATION
    69. Taamma, A; Misset, JL; Riofrio, M; Guzman, C; Brain, E; Lazaro, LL; Rosing, H; Jimeno, JM; Cvitkovic, E
      Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors

      JOURNAL OF CLINICAL ONCOLOGY
    70. Fleming, GF; Fowler, JM; Waggoner, SE; Copeland, LJ; Greer, BE; Horowitz, I; Sutton, G; Schilder, RJ; Fracasso, PM; Ball, HG; McGuire, WP
      Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: A Gynecologic Oncology Group Study

      JOURNAL OF CLINICAL ONCOLOGY
    71. Schrag, D; Gelfand, SE; Bach, PB; Guillem, J; Minsky, BD; Begg, CB
      Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results-medicare

      JOURNAL OF CLINICAL ONCOLOGY
    72. Dispenzieri, A; Lacy, MQ; Kyle, RA; Therneau, TM; Larson, DR; Rajkumar, SV; Fonseca, R; Greipp, PR; Witzig, TE; Lust, JA; Gertz, MA
      Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival

      JOURNAL OF CLINICAL ONCOLOGY
    73. Djavan, B; Waldert, M; Seitz, C; Marberger, M
      Insulin-like growth factors and prostate cancer

      WORLD JOURNAL OF UROLOGY
    74. Thomas, CMG; Sweep, CGJ
      Serum tumor markers: past, state of the art, and future

      INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
    75. Surbek, DV; Holzgreve, W
      Fetal cells from cord blood as stem cell source: current status and possible implications in gynaecologic oncology

      EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
    76. Kurata, T; Tamura, T; Shinkai, T; Ohe, Y; Kunitoh, H; Kodama, T; Kakinuma, R; Matsumoto, T; Kubota, K; Omatsu, H; Nishiwaki, Y; Saijo, N
      Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer

      JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    77. Tai, CJ; Wang, WS; Liu, JH; Yen, CC; Fan, FS; Chiou, TJ; Chen, PM
      Salvage therapy with single-agent paclitaxel by three-hour infusion in metastatic breast cancer: an experience in Taipei Veterans General Hospital

      JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    78. Morreim, EH
      From the clinics to the courts: The role evidence should play in litigating medical care

      JOURNAL OF HEALTH POLITICS POLICY AND LAW
    79. Saijo, N; Tamura, T; Yamamoto, N; Nishio, K
      New strategies for cancer therapy in the 21st century

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    80. Kerr, JZ; Berg, SL; Dauser, R; Nuchtern, J; Egorin, MJ; McGuffey, A; Aleksic, A; Blaney, S
      Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    81. Ferrazzi, E; Toso, S; Zanotti, M; Giuliano, G
      Typhlitis (neutropenic enterocolitis) after a single dose of vinorelbine

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    82. Schmidinger, M; Budinsky, AC; Wenzel, C; Locker, GJ; Pluschnig, U; Brodowicz, T; Kubista, E; Maca, S; Zabernigg, A; Ilsinger, P; Seewann, L; Hojas, S; Blach, M; Zielinski, CC; Steger, GG
      Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    83. Turatti, F; Mezzanzanica, D; Nardini, E; Luison, E; Maffioli, L; Bombardieri, E; de Lalla, C; Canevari, S; Figini, M
      Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    84. Folkman, J; Browder, T; Palmblad, J
      Angiogenesis research: Guidelines for translation to clinical application

      THROMBOSIS AND HAEMOSTASIS
    85. Toffoli, G; Corona, G; Sorio, R; Robieux, I; Basso, B; Colussi, AM; Boiocchi, M
      Population pharmacokinetics and pharmacodynamics of oral etoposide

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    86. Baker, AF; Dorr, RT
      Drug interactions with the taxanes: clinical implications

      CANCER TREATMENT REVIEWS
    87. Bertolini, A; Fiumano, M; Fusco, O; Muffatti, A; Scarinci, A; Pontiggia, G; Scopelliti, M
      Acute cardiotoxicity during capecitabine treatment: A case report

      TUMORI
    88. Nabholtz, JM
      Docetaxel (Taxotere (R)) combined with anthracycline, Xeloda (R) and new pharmaceuticals

      TUMORI
    89. Ficorella, C
      Docetaxel (Taxotere (R)) combined with trastuzumab (Herceptin)

      TUMORI
    90. Baltali, E; Ozisik, Y; Guler, N; Firat, D; Altundag, K
      Combination of docetaxel and doxorubicin as first-line chemotherapy in metastatic breast cancer

      TUMORI
    91. Mokbel, K; Hassanally, D
      From HER2 to herceptin

      CURRENT MEDICAL RESEARCH AND OPINION
    92. Gunnars, B; Nygren, P; Glimelius, B
      Assessment of quality of life during chemotherapy

      ACTA ONCOLOGICA
    93. Karlsson, G; Nygren, P; Glimelius, B
      Economic aspects of chemotherapy

      ACTA ONCOLOGICA
    94. Mazumdar, M; Fazzari, M; Panageas, KS
      A standardization method to adjust for the effect of patient selection in phase II clinical trials

      STATISTICS IN MEDICINE
    95. Recchia, F; De Filippis, S; Rosselli, M; Saggio, G; Pompili, P; Piccinini, M; Rea, S
      Combined 5-fluorouracil infusion with fractionated epirubicin and cyclophosphamide in advanced breast cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    96. Murad, AM; Guimaraes, RC; Aragao, BC; Scalabrini-Neto, AO; Rodrigues, VH; Garcia, R
      Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    97. Matheny, CJ; Lamb, MW; Brouwer, KLR; Pollack, GM
      Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation

      PHARMACOTHERAPY
    98. Petersen, S; Benishek, LA
      Social construction of illness: Addressing the impact of cancer on women in therapy

      WOMEN & THERAPY
    99. Porrata, LF; Ingle, JN; Litzow, MR; Geyer, S; Markovic, SN
      Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer

      BONE MARROW TRANSPLANTATION
    100. Elias, AD; Richardson, P; Avigan, D; Ibrahim, J; Joyce, R; McDermott, D; Levine, J; Warren, D; McCauley, M; Wheeler, C; Frei, E
      A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies

      BONE MARROW TRANSPLANTATION


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/10/20 alle ore 01:14:14